AIM ImmunoTech Inc (AIM)
0.28
+0.01
(+3.70%)
USD |
NYAM |
Sep 27, 16:00
0.2799
0.00 (0.00%)
After-Hours: 20:00
AIM ImmunoTech SG&A Expense (TTM): 22.70M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 22.70M |
March 31, 2024 | 22.66M |
December 31, 2023 | 21.14M |
September 30, 2023 | 13.79M |
June 30, 2023 | 13.52M |
March 31, 2023 | 13.15M |
December 31, 2022 | 12.93M |
September 30, 2022 | 12.04M |
June 30, 2022 | 8.669M |
March 31, 2022 | 8.633M |
December 31, 2021 | 8.673M |
September 30, 2021 | 8.64M |
June 30, 2021 | 8.926M |
March 31, 2021 | 8.498M |
December 31, 2020 | 8.654M |
September 30, 2020 | 7.554M |
June 30, 2020 | 7.315M |
March 31, 2020 | 7.54M |
December 31, 2019 | 7.039M |
September 30, 2019 | 7.187M |
June 30, 2019 | 6.614M |
March 31, 2019 | 6.405M |
December 31, 2018 | 6.201M |
September 30, 2018 | 6.302M |
June 30, 2018 | 6.585M |
Date | Value |
---|---|
March 31, 2018 | 6.471M |
December 31, 2017 | 6.572M |
September 30, 2017 | 6.799M |
June 30, 2017 | 6.877M |
March 31, 2017 | 6.897M |
December 31, 2016 | 7.681M |
September 30, 2016 | 7.268M |
June 30, 2016 | 7.319M |
March 31, 2016 | 7.682M |
December 31, 2015 | 7.147M |
September 30, 2015 | 7.447M |
June 30, 2015 | 7.936M |
March 31, 2015 | 8.431M |
December 31, 2014 | 9.057M |
September 30, 2014 | 8.969M |
June 30, 2014 | 8.865M |
March 31, 2014 | 8.185M |
December 31, 2013 | 7.723M |
September 30, 2013 | 9.749M |
June 30, 2013 | 9.338M |
March 31, 2013 | 9.259M |
December 31, 2012 | 9.056M |
September 30, 2012 | 7.072M |
June 30, 2012 | 7.048M |
March 31, 2012 | 6.766M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
7.039M
Minimum
Dec 2019
22.70M
Maximum
Jun 2024
11.46M
Average
8.671M
Median
SG&A Expense (TTM) Benchmarks
Perspective Therapeutics Inc | 18.64M |
Protalix BioTherapeutics Inc | 14.41M |
Electromed Inc | 34.49M |
Xtant Medical Holdings Inc | 79.82M |
Armata Pharmaceuticals Inc | 13.38M |